Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability Study of VRDN-001 in Thyroid Eye Disease
2023-507563-19-00Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, randomised trial of veligrotug in Graves Orbitopathy (GO) (2 arms), sponsored by Viridian Therapeutics. Primary endpoint: Treatment Emergent Adverse Event incidence rate through Week 15. Started Oct 2024; status: completed.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-507563-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507563-19-00.